{
  "meta": {
    "id": "test3",
    "title": "309_Pharmacology_MIQ_Series",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "A 72-year-old man with Parkinson\u2019s disease presents for a routine follow-up. He reports improvement in his tremor and bradykinesia but is concerned about a recent development of a net-like purplish discoloration on his lower legs, which worsens in cold weather. He denies pain or itching. His medications include carbidopa-levodopa, pramipexole, and a recently added agent for dyskinesia control. Which of the following medications is MOST likely responsible for his skin changes?",
      "options": [
        {
          "label": "A",
          "text": "Amantadine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Levodopa",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pramipexole",
          "correct": false
        },
        {
          "label": "D",
          "text": "Selegiline",
          "correct": false
        }
      ],
      "correct_answer": "A. Amantadine",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/1(1235).png"
      ],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 A. Amantadine \u2013 Correct \u2022    Used in Parkinson\u2019s disease for treatment of levodopa-induced dyskinesias. \u2022    Mechanism: NMDA receptor antagonist with dopaminergic effects. \u2022    Side Effect: Livedo reticularis is a unique and characteristic adverse effect. \u2022    Usually reversible upon discontinuation of the drug.</li><li>\u2022 B. Levodopa \u2022    Mainstay treatment for Parkinson\u2019s disease. \u2022    May cause motor fluctuations and dyskinesia, but does not cause livedo reticularis. \u2022    Skin reactions are rare.</li><li>\u2022 C. Pramipexole \u2022    Dopamine agonist. \u2022    Can cause sleep attacks, impulse control disorders, and hypotension, but not associated with skin discoloration.</li><li>\u2022 D. Selegiline \u2022    MAO-B inhibitor used as adjunct therapy. \u2022    May cause insomnia, nausea, and serotonin syndrome if combined improperly. \u2022    No association with livedo reticularis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1b2a3157",
      "audio": ""
    },
    {
      "text": "Find out false statement",
      "options": [
        {
          "label": "A",
          "text": "Azithromycin associated with tendon rupture, particularly in older adults",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ciprofloxacin inhibits DNA gyrase and topoisomerase IV",
          "correct": false
        },
        {
          "label": "C",
          "text": "Imipenem is resistant to beta-lactamase degradation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Linezolid is bacteriostatic",
          "correct": false
        }
      ],
      "correct_answer": "A. Azithromycin associated with tendon rupture, particularly in older adults",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 A. Azithromycin is associated with tendon rupture \u2014 FALSE \u2022    Azithromycin is a macrolide antibiotic, mainly associated with: o    QT prolongation o    GI upset \u2022    It does NOT cause tendon rupture. \u2022    Tendon rupture is a known side effect of fluoroquinolones (like ciprofloxacin), especially in older adults and those on corticosteroids.</li><li>\u2022 B. Ciprofloxacin inhibits DNA gyrase and topoisomerase IV \u2014 TRUE \u2022    Ciprofloxacin, a fluoroquinolone, targets: o    DNA gyrase in Gram-negative bacteria o    Topoisomerase IV in Gram-positive bacteria \u2022    This disrupts bacterial DNA replication and transcription \u2014 bactericidal effect</li><li>\u2022 C. Imipenem is resistant to beta-lactamase degradation \u2014 TRUE \u2022    Imipenem is a carbapenem antibiotic. \u2022    It is broad-spectrum and resistant to most \u03b2-lactamases (except metallo-\u03b2-lactamases). \u2022    Often used with cilastatin to inhibit renal degradation.</li><li>\u2022 D. Linezolid is bacteriostatic \u2014 TRUE \u2022    Linezolid is an oxazolidinone antibiotic. \u2022    Inhibits the initiation of bacterial protein synthesis (binds 50S subunit). \u2022    Bacteriostatic against most organisms (except bactericidal for streptococci). \u2022    Used for MRSA, VRE, and drug-resistant Gram-positives</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d2564488",
      "audio": ""
    },
    {
      "text": "Which of the following anti-helminthic drugs causes neuromuscular blockade leading to worm spastic paralysis?",
      "options": [
        {
          "label": "A",
          "text": "Albendazole",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ivermectin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Praziquantel",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pyrantel pamoate",
          "correct": true
        }
      ],
      "correct_answer": "D. Pyrantel pamoate",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/2(1006).png"
      ],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 Why the Other Options Are Incorrect:</li><li>\u2022 A. Albendazole \u2022    Mechanism: Inhibits microtubule polymerization by binding \u03b2-tubulin. \u2022    Disrupts cellular transport and glucose uptake \u2192 energy depletion \u2192 death. \u2022    Used for broad-spectrum helminthic infections (e.g., neurocysticercosis, echinococcus). \u2022    No neuromuscular action.</li><li>\u2022 B. Ivermectin \u2022    Mechanism: Binds to glutamate-gated chloride channels, leading to paralysis by hyperpolarization of nerve and muscle cells. \u2022    Used for strongyloidiasis and onchocerciasis (river blindness). \u2022    Though it leads to paralysis, it\u2019s not via nicotinic blockade and thus different from pyrantel\u2019s neuromuscular blockade.</li><li>\u2022 C. Praziquantel \u2022    Mechanism: Increases membrane permeability to calcium, causing tetanic contraction and paralysis of flukes and tapeworms. \u2022    Used mainly for schistosomiasis and cestode (tapeworm) infections. \u2022    Acts via calcium influx, not neuromuscular blockade.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c0cec37a",
      "audio": ""
    },
    {
      "text": "A patient with schizophrenia presents to the ED with high fever, lead-pipe rigidity, and elevated CK levels. Which drug is most likely responsible?",
      "options": [
        {
          "label": "A",
          "text": "Clozapine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aripiprazole",
          "correct": false
        },
        {
          "label": "C",
          "text": "Risperidone",
          "correct": true
        },
        {
          "label": "D",
          "text": "Quetiapine",
          "correct": false
        }
      ],
      "correct_answer": "C. Risperidone",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/3(879).png"
      ],
      "explanation": "<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "99419f8e",
      "audio": ""
    },
    {
      "text": "A 62-year-old woman with a history of diabetes presents with a painful, vesicular rash distributed along the right thoracic dermatome. Which of the following is the most appropriate antiviral therapy?",
      "options": [
        {
          "label": "A",
          "text": "Acyclovir",
          "correct": true
        },
        {
          "label": "B",
          "text": "Oseltamivir",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ribavirin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tecovirimat",
          "correct": false
        }
      ],
      "correct_answer": "A. Acyclovir",
      "question_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/4(796).png"
      ],
      "explanation_images": [],
      "explanation": "<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "300617e2",
      "audio": ""
    },
    {
      "text": "A 45-year-old man on an antidepressant for major depression presents with myoclonus, hyperreflexia, and agitation. He was recently started on linezolid for an infection. What drug useful for treating these symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Vilazodone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fluoxetine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cyproheptadine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Amitriptyline",
          "correct": false
        }
      ],
      "correct_answer": "C. Cyproheptadine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "77564aa0",
      "audio": ""
    },
    {
      "text": "Find out the true statements A. Phenobarbital is the first-line drug for treating seizures in neonates B. lacosamide enhances fast inactivation of voltage-gated sodium channels C. Ethosuximide is prescribed an antiepileptic for absence seizures with myoclonic jerk D. Cannabidiol useful in Dravet syndrome E. Oxcarbazepine has less risk of SIADH than carbamazepine",
      "options": [
        {
          "label": "A",
          "text": "A, B & C",
          "correct": false
        },
        {
          "label": "B",
          "text": "B, C & D",
          "correct": false
        },
        {
          "label": "C",
          "text": "A & E",
          "correct": false
        },
        {
          "label": "D",
          "text": "A & D",
          "correct": true
        }
      ],
      "correct_answer": "D. A & D",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 Phenobarbital is widely accepted as the first-line treatment for neonatal seizures. It enhances GABA-A receptor activity, leading to neuronal inhibition. Despite sedative effects, it is effective in immature brains where GABA can still have depolarizing effects.</li><li>\u2022 Lacosamide enhances slow inactivation of voltage-gated sodium channels, not fast inactivation.</li><li>\u2022 Ethosuximide is first-line for pure absence seizures, but not for myoclonic jerks.</li><li>\u2022 In absence with myoclonus (e.g., juvenile myoclonic epilepsy), valproic acid is preferred.</li><li>\u2022 Cannabidiol (CBD) is approved for Dravet syndrome, a rare and severe form of childhood epilepsy. It reduces seizure frequency and is used as adjunctive therapy.  Cannabidiol also approved for Lennox-Gastaut Syndrome and Tuberous Sclerosis Complex (TSC).</li><li>\u2022 Oxcarbazepine is actually more associated with hyponatremia and SIADH than carbamazepine, especially in elderly patients. Monitoring sodium is essential.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "44ba1ad1",
      "audio": ""
    },
    {
      "text": "Which of the following is the most appropriate antidote for cyanide poisoning?",
      "options": [
        {
          "label": "A",
          "text": "N-acetylcysteine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hydroxocobalamin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Flumazenil",
          "correct": false
        },
        {
          "label": "D",
          "text": "Amyl nitrite",
          "correct": false
        }
      ],
      "correct_answer": "B. Hydroxocobalamin",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/5(755).png"
      ],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 Antidote: Hydroxocobalamin \u2022    Mechanism: Binds cyanide to form cyanocobalamin (vitamin B12), which is excreted in the urine. \u2022    Advantages: o    Acts rapidly o    Does not lower blood pressure (unlike nitrites) o    Preferred in smoke inhalation victims, where coexisting carbon monoxide poisoning is a risk Key Point: Hydroxocobalamin is the first-line treatment for cyanide poisoning, especially in emergency and prehospital settings.</li><li>\u2022 Why the Other Options Are Incorrect:</li><li>\u2022 A. N-acetylcysteine (NAC) \u2022    Used for: Acetaminophen (paracetamol) toxicity \u2022    Mechanism: Replenishes glutathione stores to detoxify NAPQI \u2022    No role in cyanide poisoning</li><li>\u2022 C. Flumazenil \u2022    Used for: Benzodiazepine overdose \u2022    Mechanism: GABA-A receptor antagonist \u2022    Dangerous if mixed drug ingestion (can cause seizures) \u2022    Not relevant to cyanide toxicity</li><li>\u2022 D. Amyl nitrite \u2022    Was part of an older cyanide antidote kit \u2022    Mechanism: Induces methemoglobinemia, which binds cyanide, forming cyanmethemoglobin \u2022    However, this reduces oxygen-carrying capacity and can worsen hypoxia, especially in smoke inhalation victims \u2022    No longer first-line; used only when hydroxocobalamin is unavailable</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a7cadcf1",
      "audio": ""
    },
    {
      "text": "Which of the following reactions is a Phase I metabolic transformation that typically introduces a polar functional group?",
      "options": [
        {
          "label": "A",
          "text": "Glucuronidation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sulfation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hydroxylation",
          "correct": true
        },
        {
          "label": "D",
          "text": "Acetylation",
          "correct": false
        }
      ],
      "correct_answer": "C. Hydroxylation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f33099bd",
      "audio": ""
    },
    {
      "text": "Which monoclonal antibody binds VEGF-A, inhibiting angiogenesis in metastatic cancers?",
      "options": [
        {
          "label": "A",
          "text": "Trastuzumab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bevacizumab",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cetuximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Rituximab",
          "correct": false
        }
      ],
      "correct_answer": "B. Bevacizumab",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/6(634).png"
      ],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 A. Trastuzumab \u2022    Target: HER2/neu receptor (ERBB2) \u2022    Use: HER2-positive breast cancer and gastric cancer \u2022    Mechanism: Inhibits proliferation of HER2-overexpressing cells \u2022    Does NOT bind VEGF-A</li><li>\u2022 C. Cetuximab \u2022    Target: Epidermal Growth Factor Receptor (EGFR) \u2022    Use: Colorectal cancer (KRAS wild-type), head and neck squamous cell carcinoma \u2022    Mechanism: Blocks EGFR signaling, inhibiting cell proliferation \u2022    Does NOT inhibit angiogenesis via VEGF-A</li><li>\u2022 D. Rituximab \u2022    Target: CD20 antigen on B cells \u2022    Use: o    Non-Hodgkin lymphoma o    Chronic lymphocytic leukemia (CLL) o    Rheumatoid arthritis o    ANCA-associated vasculitis \u2022    Mechanism: B-cell depletion \u2022    Unrelated to VEGF or angiogenesis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3db0ee2c",
      "audio": ""
    },
    {
      "text": "Which agent causes maximum risk of hand-foot syndrome?",
      "options": [
        {
          "label": "A",
          "text": "Capecitabine",
          "correct": true
        },
        {
          "label": "B",
          "text": "5-Fluorouracil",
          "correct": false
        },
        {
          "label": "C",
          "text": "Methotrexate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cytarabine",
          "correct": false
        }
      ],
      "correct_answer": "A. Capecitabine",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/7(560).png"
      ],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 A. Capecitabine \u2013 Correct \u2022    Class: Oral prodrug of 5-Fluorouracil (5-FU) \u2022    Mechanism: Converted to 5-FU in the body, inhibiting thymidylate synthase \u2192 DNA synthesis inhibition \u2022    Unique Feature: o    Has high and prolonged exposure in skin tissues, especially hands and feet. o    Causes dose-limiting and more frequent hand-foot syndrome compared to IV 5-FU. \u2022    Clinical Use: Breast cancer, colorectal cancer, gastric cancer \u2022    Management: o    Dose reduction or interruption o    Emollients, urea cream, cooling, and sometimes pyridoxine (though evidence is limited)</li><li>\u2022 B. 5-Fluorouracil (5-FU) \u2022    Also causes hand-foot syndrome but less frequently and less severely than capecitabine. \u2022    IV 5-FU is less concentrated in peripheral tissues, leading to lower risk.</li><li>\u2022 C. Methotrexate \u2022    Folate antagonist; used in cancer, autoimmune diseases, and ectopic pregnancy \u2022    Common toxicities: mucositis, hepatotoxicity, myelosuppression \u2022    Not typically associated with hand-foot syndrome</li><li>\u2022 D. Cytarabine \u2022    Antimetabolite used mainly in acute leukemias \u2022    Common toxicities: cerebellar toxicity, myelosuppression, chemical conjunctivitis \u2022    Hand-foot syndrome is rare with this drug</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9e7b0164",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is approved for use in chronic Immune Thrombocytopenia (ITP) refractory to first-line therapies?",
      "options": [
        {
          "label": "A",
          "text": "Fostamatinib",
          "correct": true
        },
        {
          "label": "B",
          "text": "Oprelvikin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Abciximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Eltrombopag",
          "correct": false
        }
      ],
      "correct_answer": "A. Fostamatinib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a8fa86a5",
      "audio": ""
    },
    {
      "text": "Which agent is used in rheumatoid arthritis and acts by inhibiting dihydroorotate dehydrogenase, blocking pyrimidine synthesis?",
      "options": [
        {
          "label": "A",
          "text": "Leflunomide",
          "correct": true
        },
        {
          "label": "B",
          "text": "Methotrexate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Azathioprine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hydroxychloroquine",
          "correct": false
        }
      ],
      "correct_answer": "A. Leflunomide",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/8(522).png"
      ],
      "explanation": "<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c6723348",
      "audio": ""
    },
    {
      "text": "Which of the following drugs targets the \u03b14\u03b27 integrin and is useful in the treatment of Crohn\u2019s disease?",
      "options": [
        {
          "label": "A",
          "text": "Aprepitant",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vedolizumab",
          "correct": true
        },
        {
          "label": "C",
          "text": "Natalizumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ustekinumab",
          "correct": false
        }
      ],
      "correct_answer": "B. Vedolizumab",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/9(481).png"
      ],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 A. Aprepitant \u2013 Incorrect \u2022    Class: Neurokinin-1 (NK1) receptor antagonist \u2022    Use: Primarily used to prevent chemotherapy-induced nausea and vomiting. \u2022    Not involved in the treatment of inflammatory bowel disease.</li><li>\u2022 C. Natalizumab \u2013 Incorrect \u2022    Mechanism: Targets \u03b14-integrin, but not selectively for \u03b14\u03b27. \u2022    Use: Approved for multiple sclerosis and Crohn\u2019s disease, but associated with progressive multifocal leukoencephalopathy (PML) due to JC virus reactivation. \u2022    Less gut-specific than Vedolizumab, and therefore has more systemic immunosuppressive risks.</li><li>\u2022 D. Ustekinumab \u2013 Incorrect \u2022    Mechanism: Monoclonal antibody against interleukin-12 and interleukin-23. \u2022    Use: Approved for Crohn\u2019s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. \u2022    While it is effective for Crohn\u2019s disease, it does not target \u03b14\u03b27 integrin.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1a3fb6c6",
      "audio": ""
    },
    {
      "text": "What is the primary target of inclisiran, a novel lipid-lowering agent?",
      "options": [
        {
          "label": "A",
          "text": "Citrate lyase",
          "correct": false
        },
        {
          "label": "B",
          "text": "Niemann-Pick C1-Like 1 (NPC1L1)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Microsomal TG transfer protein",
          "correct": false
        },
        {
          "label": "D",
          "text": "PCSK9 mRNA via siRNA",
          "correct": true
        }
      ],
      "correct_answer": "D. PCSK9 mRNA via siRNA",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/10(428).png"
      ],
      "explanation": "<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "47af9d7a",
      "audio": ""
    },
    {
      "text": "A patient with HFrEF on full-dose ARNI therapy continues to have high resting HR. Which drug reduces HR without affecting contractility or BP?",
      "options": [
        {
          "label": "A",
          "text": "Bisoprolol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ivabradine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Verapamil",
          "correct": false
        },
        {
          "label": "D",
          "text": "Amiodarone",
          "correct": false
        }
      ],
      "correct_answer": "B. Ivabradine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 B. Ivabradine \u2013 Correct Answer \u2022    Mechanism: Selective inhibitor of the funny current (If) in the sinoatrial node. \u2022    Effect: Slows heart rate without affecting: o    Myocardial contractility o    Blood pressure \u2022    Indication: o    Symptomatic HFrEF (EF \u226435%) o    Sinus rhythm o    Resting heart rate \u226570 bpm o    Despite maximally tolerated beta-blocker or if beta-blockers are contraindicated \u2022    Unique Feature: Does not depress myocardial function or lower systemic BP, making it especially useful in patients with low BP or borderline EF.</li><li>\u2022 A. Bisoprolol \u2013 Incorrect \u2022    Beta-1 selective blocker, part of guideline-directed therapy for HFrEF. \u2022    Reduces HR and BP, and negatively affects contractility initially. \u2022    May not be tolerated in patients with already low blood pressure or severe HF symptoms.</li><li>\u2022 C. Verapamil \u2013 Incorrect \u2022    Non-dihydropyridine calcium channel blocker \u2022    Reduces HR, BP, and negatively inotropic (decreases contractility). \u2022    Contraindicated in HFrEF due to risk of worsening heart failure.</li><li>\u2022 D. Amiodarone \u2013 Incorrect \u2022    Primarily an antiarrhythmic; does have rate-slowing effects. \u2022    Has complex effects: blocks sodium, potassium, and calcium channels and beta-adrenergic receptors. \u2022    Not a first-line rate control agent in HFrEF for sinus tachycardia. \u2022    Significant toxicity (pulmonary, hepatic, thyroid) with chronic use.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "93acd1e4",
      "audio": ""
    },
    {
      "text": "Which of the following DIURETIC is used in pseudotumor cerebri (idiopathic intracranial hypertension)?",
      "options": [
        {
          "label": "A",
          "text": "Acetazolamide",
          "correct": true
        },
        {
          "label": "B",
          "text": "Amiloride",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mannitol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Furosemide",
          "correct": false
        }
      ],
      "correct_answer": "A. Acetazolamide",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/11(374).png"
      ],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 A. Acetazolamide \u2013 Correct \u2022    Class: Carbonic anhydrase inhibitor \u2022    Mechanism: o    Inhibits carbonic anhydrase in the choroid plexus, reducing cerebrospinal fluid (CSF) production o    Also acts in the proximal tubule of the nephron \u2022    Effect: Lowers intracranial pressure by decreasing CSF volume \u2022    First-line treatment for pseudotumor cerebri</li><li>\u2022 Why the Other Options Are Incorrect:</li><li>\u2022 B. Amiloride \u2022    Potassium-sparing diuretic; blocks ENaC in the collecting duct \u2022    No effect on CSF production or ICP \u2022    Not used in pseudotumor cerebri</li><li>\u2022 C. Mannitol \u2022    Osmotic diuretic \u2022    Used in acute management of intracranial hypertension (e.g., head trauma), but not suitable for chronic idiopathic intracranial hypertension \u2022    Works by drawing fluid out of brain parenchyma, but not used long-term</li><li>\u2022 D. Furosemide \u2022    Loop diuretic; inhibits Na\u207a/K\u207a/2Cl\u207b cotransporter in the loop of Henle \u2022    Occasionally used adjunctively, but not first-line \u2022    Does not significantly reduce CSF production</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "58ff4514",
      "audio": ""
    },
    {
      "text": "Regarding Ranolazine, all of the following are true EXCEPT:",
      "options": [
        {
          "label": "A",
          "text": "Reduces cardiac fatty acid oxidation and stimulates glucose metabolism",
          "correct": false
        },
        {
          "label": "B",
          "text": "It has weak \u03b2 receptor blocking activity",
          "correct": false
        },
        {
          "label": "C",
          "text": "It blocks late sodium channels",
          "correct": false
        },
        {
          "label": "D",
          "text": "Produces QT prolongation with significant torsades de pointes",
          "correct": true
        }
      ],
      "correct_answer": "D. Produces QT prolongation with significant torsades de pointes",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/12(364).png"
      ],
      "explanation": "<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2ebd9b1b",
      "audio": ""
    },
    {
      "text": "A 56-year-old diabetic patient with NYHA Class III heart failure is started on a new oral anti-diabetic medication. Two weeks later, he presents with weight gain and worsening peripheral edema. Which of the following medications is MOST likely responsible?",
      "options": [
        {
          "label": "A",
          "text": "Dapagliflozin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glimepiride",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pioglitazone",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sitagliptin",
          "correct": false
        }
      ],
      "correct_answer": "C. Pioglitazone",
      "question_images": [],
      "explanation_images": [
        "https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/13(324).png"
      ],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 C. Pioglitazone \u2013 Correct Answer \u2022    Class: Thiazolidinedione (TZD) \u2022    Mechanism: Activates PPAR-\u03b3 receptors, increasing insulin sensitivity in adipose tissue, liver, and skeletal muscle. \u2022    Adverse Effects: o    Fluid retention o    Weight gain o    Peripheral edema o    Can worsen heart failure, particularly NYHA Class III and IV \u2022    Contraindication: Avoid in symptomatic heart failure due to risk of volume overload and edema.</li><li>\u2022 A. Dapagliflozin \u2022    Class: SGLT2 inhibitor \u2022    Mechanism: Promotes renal glucose excretion \u2022    Effects: o    Weight loss o    Reduction in heart failure hospitalizations o    Diuretic-like effect (mild natriuresis) \u2022    Important: Dapagliflozin is beneficial in patients with HFrEF and reduces fluid overload, not causes it.</li><li>\u2022 B. Glimepiride \u2022    Class: Sulfonylurea \u2022    Mechanism: Stimulates insulin secretion from pancreatic \u03b2-cells \u2022    Adverse Effects: o    Hypoglycemia o    Weight gain \u2022    Does not typically cause edema or worsen heart failure.</li><li>\u2022 D. Sitagliptin \u2022    Class: DPP-4 inhibitor \u2022    Mechanism: Increases endogenous GLP-1 levels \u2192 enhances insulin release and decreases glucagon \u2022    Generally weight-neutral \u2022    Minimal risk of edema \u2022    Some agents in this class (e.g., saxagliptin) have been associated with HF risk, but sitagliptin itself is not clearly linked to worsening HF or edema.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "15f1b06e",
      "audio": ""
    },
    {
      "text": "A 68-year-old man, 3 days post-TURP, reports lower abdominal fullness and inability to void. He is stable, with a distended bladder and post-void residual of 550 mL on ultrasound. Neurologic exam is normal, and catheterization drains clear urine. Which cholinergic agent is most appropriate to stimulate bladder emptying?",
      "options": [
        {
          "label": "A",
          "text": "Bethanechol",
          "correct": true
        },
        {
          "label": "B",
          "text": "Physostigmine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Carbachol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Donepezil",
          "correct": false
        }
      ],
      "correct_answer": "A. Bethanechol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p>\n<ul><li>\u2022 Why Bethanechol? \u2022    Mechanism: Direct muscarinic receptor agonist (primarily M3) \u2192 activates bladder smooth muscle. \u2022    Use: Indicated for non-obstructive urinary retention and neurogenic bladder. \u2022    Promotes bladder contraction and facilitates micturition.</li><li>\u2022 Why the Other Options Are Wrong: \u2022    B. Physostigmine: o    Indirect cholinergic agonist (reversible AChE inhibitor), crosses BBB \u2192 mostly CNS effects. o    Used to reverse anticholinergic toxicity, not to stimulate bladder directly. \u2022    C. Carbachol: o    Potent cholinergic agonist with both muscarinic and nicotinic activity, mostly used topically in glaucoma. o    Not suitable systemically due to risk of uncontrolled cholinergic effects. \u2022    D. Donepezil: o    Centrally acting AChE inhibitor, used in Alzheimer\u2019s disease. o    No role in treating bladder dysfunction or stimulating peripheral M3 receptors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9964219c",
      "audio": ""
    }
  ]
}